Immix Cash vs Accounts Payable Analysis
| IMMX Stock | USD 1.79 0.11 6.55% |
Immix Biopharma financial indicator trend analysis is infinitely more than just investigating Immix Biopharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immix Biopharma is a good investment. Please check the relationship between Immix Biopharma Cash and its Accounts Payable accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immix Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.
Cash vs Accounts Payable
Cash vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immix Biopharma Cash account and Accounts Payable. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Immix Biopharma's Cash and Accounts Payable is 0.52. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Immix Biopharma, assuming nothing else is changed. The correlation between historical values of Immix Biopharma's Cash and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of Immix Biopharma are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Cash i.e., Immix Biopharma's Cash and Accounts Payable go up and down completely randomly.
Correlation Coefficient | 0.52 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Cash
Cash refers to the most liquid asset of Immix Biopharma, which is listed under current asset account on Immix Biopharma balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Immix Biopharma customers. The amounts must be unrestricted with restricted cash listed in a different Immix Biopharma account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Accounts Payable
An accounting item on the balance sheet that represents Immix Biopharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Immix Biopharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from Immix Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immix Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immix Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.At this time, Immix Biopharma's Selling General Administrative is fairly stable compared to the past year. Enterprise Value is likely to rise to about 28.8 M in 2024, whereas Tax Provision is likely to drop slightly above 12.5 K in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 1.4M | 8.2M | 16.1M | 16.9M | Cost Of Revenue | 2.5K | 2.1K | 5.5K | 3.0K |
Immix Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
Immix Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.